External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes by van Dieren, S. et al.
ARTICLE
External validation of the UK Prospective Diabetes Study
(UKPDS) risk engine in patients with type 2 diabetes
S. van Dieren & L. M. Peelen & U. Nöthlings & Y. T. van der Schouw &
G. E. H. M. Rutten & A. M. W. Spijkerman & D. L. van der A & D. Sluik & H. Boeing &
K. G. M. Moons & J. W. J. Beulens
Received: 11 August 2010 /Accepted: 8 October 2010 /Published online: 14 November 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis Treatment guidelines recommend the UK
Prospective Diabetes Study (UKPDS) risk engine for
predicting cardiovascular risk in patients with type 2
diabetes, although validation studies showed moderate
performance. The methods used in these validation studies
were diverse, however, and sometimes insufficient. Hence,
we assessed the discrimination and calibration of the
UKPDS risk engine to predict 4, 5, 6 and 8 year
cardiovascular risk in patients with type 2 diabetes.
Methods The cohort included 1,622 patients with type 2
diabetes. During a mean follow-up of 8 years, patients were
followed for incidence of CHD and cardiovascular disease
(CVD). Discrimination and calibration were assessed for 4,
5, 6 and 8 year risk. Discrimination was examined using the
c-statistic and calibration by visually inspecting calibration
plots and calculating the Hosmer–Lemeshow χ
2 statistic.
Results The UKPDS risk engine showed moderate to poor
discrimination for both CHD and CVD (c-statistic of 0.66
for both 5 year CHD and CVD risks), and an overestima-
tion of the risk (224% and 112%). The calibration of the
UKPDS risk engine was slightly better for patients with
type 2 diabetes who had been diagnosed with diabetes more
than 10 years ago compared with patients diagnosed more
recently, particularly for 4 and 5 year predicted CVD and
CHD risks. Discrimination for these periods was still
moderate to poor.
Conclusions/interpretation We observed that the UKPDS
risk engine overestimates CHD and CVD risk. The
discriminative ability of this model is moderate, irrespective
of various subgroup analyses. To enhance the prediction of
CVD in patients with type 2 diabetes, this model should be
updated.
Keywords Calibration.Cardiovascular disease.Coronary
heart disease.Discrimination.Epidemiology.Multiple
imputation.Prediction.Type 2 diabetes mellitus.
Validation
Abbreviations
CVD Cardiovascular disease
EPIC European Prospective Investigation into
Cancer and Nutrition
FRS Framingham risk score
HLχ
2 Hosmer–Lemeshow χ
2 statistic
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-010-1960-0) contains supplementary material,
which is available to authorised users.
S. van Dieren (*): L. M. Peelen: Y. T. van der Schouw:
G. E. H. M. Rutten: K. G. M. Moons:J. W. J. Beulens
Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht,
Str. 6.131, P.O. Box 85500, 3508 GA Utrecht, The Netherlands
e-mail: S.vanDieren@umcutrecht.nl
U. Nöthlings: D. Sluik:H. Boeing
Department of Epidemiology,
German Institute of Human Nutrition Potsdam-Rehbrücke,
Nuthetal, Germany
U. Nöthlings
Section of Epidemiology, Institute for Experimental Medicine,
Christian-Albrechts University of Kiel,
Kiel, Germany
A. M. W. Spijkerman
Centre for Prevention and Health Services Research,
National Institute of Public Health and the Environment (RIVM),
Bilthoven, The Netherlands
D. L. van der A
Centre for Nutrition and Health,
National Institute of Public Health and the Environment (RIVM),
Bilthoven, The Netherlands
Diabetologia (2011) 54:264–270
DOI 10.1007/s00125-010-1960-0ICD International Classification of Diseases
MI Multiple imputation
UKPDS UK Prospective Diabetes Study
MORGEN Monitoring Project on Risk Factors for
Chronic Diseases
SCORE Systematic Coronary Risk Evaluation
Introduction
Cardiovascular disease (CVD) is a major cause of death in
patients with type 2 diabetes, with risk for developing CHD
increased two- to fourfold [1]. Practice guidelines recom-
mend calculating CVD risk for treatment of cardiovascular
complications. Several risk equations are available to
estimate CVD risk, such as the Systematic Coronary Risk
Evaluation (SCORE) [2] and Framingham Risk Score
(FRS) [3] for the general (non-diabetic) population. The
ability of SCORE and FRS to distinguish between those at
low and high risk (discrimination) is only moderate and the
ability to correctly quantify the observed absolute risks
(calibration) is poor in patients with type 2 diabetes [4, 5].
A few prediction scores have been developed specifical-
ly for diabetes patients, either newly detected patients or
those already receiving treatment [6–10], of which the UK
Prospective Diabetes Study (UKPDS) risk engine is most
widely known and used. It estimates absolute CHD risk
using traditional risk factors such as BMI, age, sex,
smoking, systolic blood pressure and ratio of total choles-
terol to HDL-cholesterol, plus the diabetes-specific factors
duration of diabetes and HbA1c (see Electronic supplemen-
tary material [ESM] text and ESM Table 1)[ 8]. Several
studies have validated the UKPDS risk engine with
inconsistent results, as shown in a recent systematic review
[4–7, 11, 12]. In general, the discrimination of the model
was moderate and calibration poor. The methods used in the
validation studies were diverse, with different study pop-
ulations and different endpoints (e.g. CHD vs CVD), and the
calculated time period varied. Furthermore, the methods of
these validation studies could be improved. For example,
none of the studies calculating a 10 year risk accounted for
loss to follow-up or endpoints registered for a shorter
duration than 10 years, which probably biased results.
Nonetheless, guidelines promoted and funded by the
National Institute for Health and Clinical Excellence, British
CanadianguidelinesandDutchgeneralpractitionerguidelines
advocate using the UKPDS risk engine among other risk
models for risk quantification in clinical practice [13–15].
Therefore, the aim of our study was to quantify the
discrimination and calibration of the UKPDS risk engine in
a large cohort of patients with type 2 diabetes. We studied
the risk engine’s performance in prediction of cardiovascu-
lar risk over various time intervals, including 4, 5, 6 and
8 years. Furthermore, we investigated whether the duration
of diabetes or the choice of disease endpoint (CVD or
CHD) has any impact on the performance of the UKPDS
risk engine.
Methods
Study populationanddesign The study population consisted
of patients with type 2 diabetes from the Dutch and
Potsdam (Germany) contributions to the European Pro-
spective Investigation into Cancer and Nutrition (EPIC-NL
and EPIC-Potsdam, respectively). Both cohorts have been
described in more detail by Beulens et al. and Boeing et al.
[16, 17]. In brief, EPIC-NL consists of the Prospect cohort
and the Monitoring Project on Risk Factors for Chronic
Diseases (MORGEN) cohort. Prospect is a prospective
population-based cohort of 17,357 women, aged 49–
70 years, who participated in breast cancer screening
between 1993 and 1997. The MORGEN cohort consists of
22,654 men and women, aged 20–59 years, recruited from
three Dutch towns (Amsterdam, Maastricht and Doetin-
chem). From 1993 to 1997 each year a new random sample
of about 5,000 participants was examined. The EPIC-
Potsdam cohort recruited 27,548 participants between 1994
and 1998 and was based on general population registries.
In total, 1,861 individuals with type 2 diabetes were
identified at baseline; 239 patients had a history of CVD or
missing endpoint measurements and were excluded. This
resulted in 1,622 patients with type 2 diabetes for inclusion
in the current analyses. Participants from EPIC-NL were all
patients with a confirmed diagnosis of type 2 diabetes. For
EPIC-Potsdam 322 patients were confirmed as having type
2 diabetes; for 845 patients the diabetes type was
unspecified. Diabetes cases in the EPIC-NL cohort were
verified through medical records of the general practitioner
or pharmacist, while diabetes cases in EPIC-Potsdam were
verified through repeated self-report in follow-up question-
naires. All participants gave written informed consent prior
to study inclusion. Both cohorts were approved by the local
ethics committee. All information from EPIC-NL and
EPIC-Potsdam was compared, recoded and merged into
one uniform database.
Predictors and measurements At baseline, a general ques-
tionnaire containing questions on demographic character-
istics, smoking, presence of chronic diseases and other
potential risk factors was filled out by all participants. Body
weight and height were measured. Smoking was recoded
into current smokers and non-smokers (former or non-
smokers). Blood pressure was measured twice for the
participants in EPIC-NL and three times for EPIC-
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the leftarm while the participant was ina supine position. The
mean of these measurements was used in the analyses. In the
EPIC-Potsdam and Prospect cohorts systolic and diastolic
blood pressure was measured using a Boso oscillomat (Bosch
and Sohn, Jungingen, Germany). In the MORGEN cohort a
random zero sphygmomanometer (Hawksley and Sons,
Lancing, UK) was used, which slightly underestimated the
blood pressure compared with the Boso oscillomat.
Blood, 30 ml, was collected from all participants to
obtain plasma, serum and erythrocytes. Total cholesterol,
HDL- and LDL-cholesterol, and triacylglycerol levels were
measured in frozen serum samples and HbA1c was
measured in frozen erythrocytes.
Endpoints Participants were followed for two primary
outcomes: coronary events, defined as myocardial infarc-
tion and ischaemic heart disease (International Classifica-
tion of Diseases [ICD]-9 codes 410–414 [www.icd9data.
com/2007/Volume1/]; ICD-10 codes I20–I25 [www.who.
int/classifications/icd/en/]) and cardiovascular events,
defined as myocardial infarction, ischaemic heart disease
or stroke (ICD-9 codes 430–438; ICD-10 codes I60–I67,
I69). In EPIC-NL, incident morbidity cases were obtained
through linkage with the Dutch National Medical Registry,
which holds a standardised computerised database of all
hospital discharge diagnoses throughout the country. In the
Netherlands it is mandatory to fill out a hospital discharge
diagnosis whenever a patient leaves the hospital. The vital
status of EPIC-NL participants was obtained through
linkage with the municipal population registries. The
records of this database were linked to the EPIC-NL cohort
with a validated probabilistic method [18].
In EPIC-Potsdam the major source of data on incident
cases was questionnaires that were mailed to all participants
every 2 years. Of these questionnaires, 95% were returned.
Mortality data for EPIC-Potsdam participants were collected
through cooperation with the local health offices of Potsdam
and the state office of statistics of Brandenburg [19]. All
diagnoses were coded according to the ICD.
Data analysis Years at risk for developing the endpoints
were calculated as the time between enrolment in the study
and the diagnosis of one of the two endpoints (CHD or
CVD), the date of death or the end of follow-up.
Missing values occurred on various predictor variables
ranging from 4.2% (for systolic blood pressure) to 19.0%
(for HDL-cholesterol). As missing values seldom occur
completely at random, simply leaving those patients out of
the analysis yields biased results. Accordingly, it is widely
recommended to impute missing values rather than
performing a complete subject analysis [20]. We used
multiple imputation (MI) for our missing data on predictor
variables using the MI by chained equations procedure,
assuming that after correction for measured variables the
patterns of ‘missingness’ can be considered to be at random.
The 4, 5, 6 and 8 year predicted risks for CHD and CVD
were calculated using the UKPDS risk engine (see ESM).
The measurements of HbA1c, blood pressure and lipid ratio
were less precise than the estimates of the UKPDS.
Therefore, in order to prevent overestimation of the risk,
we used the beta values from the appendix of the paper as
suggested by Stevens et al. [8].
Not all participants had a follow-up of 8 years; therefore,
two types of analysis were conducted. The first analysis
included only patients with type 2 diabetes who were
followed up for at least the corresponding time; participants
with follow-up shorter than the calculated risk period were
excluded. The second analysis included all patients, with
patients with a follow-up shorter than the calculated risk
period included as non-cases.
Model performance was assessed by measuring discrim-
ination (the ability to discriminate between participants
with or without an event) and calibration (the ability to
quantify the observed absolute risk). The discriminative
ability of the model was examined by calculating the c-
statistic with 95% CI for each time period (4, 5, 6 and
8 year risk). The calibration of the model was assessed
through visually inspecting the calibration plots and by
calculating the Hosmer–Lemeshow χ
2 statistic (HLχ
2).
Estimates for the c-statistic and HLχ
2 were pooled using
Rubin’s rule, in order to correct for the MI.
To take into account the time-to-event structure of our
data, we analysed the data and assessed the discrimination
of the UKPDS risk engine using Harrell’s c-statistic for
censored data [21]. The calibration was examined by
plotting predicted survival probabilities against right-
censored failure times (using the R program, val.surv
function, developed by F. E. Harrell Jr).
As a longer duration of diagnosed diabetes is modelled in
the survival part of the risk equation rather than in the linear
predictor, each year longer duration results in a much higher
predicted CVD risk. We examined whether performance of
the UKPDS riskenginewas affectedbydurationofdiagnosed
diabetes. Separate analyses were performed for patients who
had had diabetes for over 10 years and patients who had had
diabetes for up to and including 10 years. All statistical
analyses were performed using R-2.10.1 for Windows (http://
cran.r-project.org/).
Results
During a mean exposure time of 8 years, 146 CVD cases
were identified, of which 99 were cases of CHD. Baseline
characteristics according to cohort are shown in Table 1,
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EPIC-NL there were more smokers and participants had a
higher total cholesterol/HDL-cholesterol ratio, but a shorter
duration of diabetes compared with EPIC-Potsdam partic-
ipants. Compared with the participants from the UKPDS
population in which the risk equation was developed,
EPIC-NL and EPIC-Potsdam included fewer smokers and
participants were older and had higher levels of HbA1c.
Using the UKPDS risk engine the mean predicted 8 year
risk was 15.9% while the observed 8 year CHD risk was
4.9%, resulting in an overestimation of 224%. For 8 year
CVD risk, the UKPDS risk engine overestimated the CVD
risk by 112%, as the observed 8 year CVD risk was 7.5%.
Performance of the model for CHD outcome In the first
analysis (excluding participants with a shorter follow-up than
the predicted duration) the c-statistic was 0.66 (95% CI 0.51–
0.81) for 5 year risk (Table 2). The calibration was poor
(HLχ
2=61.9, p<0.001 for 5 year risk) with a severe
overestimation of the risk (Fig. 1a). Discrimination and
calibration were similar for other calculated risk periods. In
the second analysis (including patients with a shorter follow-up
than predicted duration), the discrimination was the same as for
the first analysis (c-statistic 0.65 [95% CI 0.50–0.80]), and the
calibration was similarly poor (HLχ
2=77.4, p<0.001).
Taking into account the time-to-event structure of the data,
theoveralldiscriminationwassimilar;Harrell’sc-statistic was
0.65 (95% CI 0.53–0.76). The overall calibration was
similarly poor, showing a severe overestimation, comparable
with the plots of the first and second analyses.
Thediscriminationofthemodelforpatientswithaduration
of diabetes >10 years was similar to the discrimination of the
modelfor patients withadurationof≤10years(ESMTables2
and 3). However, the calibration was better for 4 and 5 year
risk prediction for patients with diabetes for >10 years, as the
HLχ
2 statistics were 15.2 (p=0.347) for 4 year risk and 20.8
(p=0.098) for 5 year risk, which indicates that the observed
and predicted risks did not differ significantly. For other
calculated risk periods the calibration was similarly poor for
both patient groups with up to and over 10 years of
diagnosed diabetes.
Performance of the model for CVD outcome In the first
analysis, discrimination for 5 year risk prediction was
moderate to poor, with a c-statistic of 0.66 (95% CI 0.53–
0.79) (Table 3). The calibration was poor (HLχ
2=35.2, p=
0.002) with a severe overestimation (Fig. 1b). Again,
similar results were obtained for the other calculated risk
periods. For the second analysis the discrimination for
5 year risk prediction was similar to the first analysis (c-
statistic 0.65 [95% CI 0.53–0.79]). The calibration was also
poor (HLχ
2=48.1, p<0.001), but the overestimation was
greater than for the first analysis. Overall discrimination for
CVD, taking into account the time-to-event structure of the
Table 1 Baseline characteristics by country of 1,622 participants, with baseline characteristics of the UKPDS cohort [8]
Characteristics EPIC-NL (n=455) EPIC-Potsdam (n=1,167) UKPDS (n=4,540)
Age at recruitment (years) 58.2±6.7 57.7±6.5 52.0±8.8
Male participants, % (n) 17.8 (81) 54.4 (639) 58.2 (2,643)
Systolic blood pressure (mmHg) 144±21.0 141±18.6 136±19.3
Current smoking, % (n) 23.3 (106) 18.7 (219) 30.2 (1,372)
Total cholesterol/HDL-cholesterol 5.36±1.75 4.57±1.19 5.2±1.4
HbA1c level (%) 8.13±1.79 8.27±2.34 6.7±1.4
Duration of diabetes (years) 6.7±6.7 7.6±7.3 0
Values are mean±SD unless stated otherwise
Table 2 Discrimination and calibration of the UKPDS risk engine for calculated risk periods of 4, 5, 6 and 8 years, with CHD as outcome
Calculated risk
period (years)
First analysis Second analysis
Cases/nc -statistic (95% CI) χ
2 statistic Cases/n c-statistic (95% CI) χ
2 statistic
4 48/1,508 0.65 (0.49–0.82) 44.6 (p<0.001) 48/1,622 0.65 (0.48–0.81) 53.2 (p<0.001)
5 55/1,476 0.66 (0.51–0.81) 61.9 (p<0.001) 55/1,622 0.65 (0.50–0.80) 77.4 (p<0.001)
6 63/1,438 0.66 (0.52–0.80) 78.5 (p<0.001) 63/1,622 0.65 (0.51–0.79) 104.1 (p<0.001)
8 80/1,094 0.66 (0.53–0.78) 71.7 (p<0.001) 80/1,622 0.65 (0.53–0.77) 169.8 (p<0.001)
First analysis: excluding participants with follow-up shorter than calculated risk period
Second analysis: including participants with follow-up shorter than calculated risk period
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(95% CI 0.55–0.74). The calibration plot for right censored
data was similarly poor, showing a severe overestimation
comparable with the plots of the first and second analysis.
Overall, the performance of the model for predicting
CVD was about the same as for predicting CHD. The
discriminative ability of the model was similar for patients
with up to and over 10 years of diagnosed diabetes (ESM
Tables 4 and 5).
Consistent with the results for CHD risk, the calibration
was better for patients who had diabetes for >10 years
compared with patients with diabetes ≤10 years for 4 and
5 year calculated risk periods. The HLχ
2 test was not
significant, meaning there was no significant difference
between observed and predicted risks.
Discussion
This study shows that the discriminative ability of the
UKPDS risk engine is moderate and the calibration poor,
with a severely overestimated CHD risk prediction. The
performance was similar for prediction of CVD. The
calibration of the UKPDS risk engine for 4 and 5 year
prediction was better for patients who had been diagnosed
with diabetes for >10 years compared with patients who
had been diagnosed with type 2 diabetes ≤10 years ago. But
this difference must be interpreted with caution because the
number of patients in these subgroup analyses was much
smaller, making it difficult to detect differences between
observed and predicted risks.
The strengths of this study are its large sample size of
patients with type 2 diabetes, the verification of diabetes
cases and the variety of patients (from Germany and the
Netherlands), which enhances the generalisability of the
results. However, some limitations need to be addressed.
First, the mean follow-up time was 8 years; therefore, we
could not validate 10 year CVD and CHD risks. However,
the UKPDS risk engine is, in principle, designed for all risk
periods, including periods shorter than 10 years [8].
Second, our population consisted of all diabetes cases, not
just individuals newly diagnosed with diabetes. Therefore,
we could only validate the use of the UKPDS risk engine
for patients who have been diagnosed with diabetes for
some time. Finally, we had some missing values in the
baseline factors, but we addressed this limitation using MI.
There are several explanations for the poor to moderate
performance of the UKPDS risk engine to predict CHD and
CVD risk in this population. First, the UKPDS risk engine
was developed from a cohort that started including patients
in 1977 [8]. Treatment of type 2 diabetes and prevention of
CVD has improved since 1977 and the risk of developing
CVD has declined with better treatment of type 2 diabetes
[22]. Also, as diabetes is now detected at an earlier stage,
therapeutic intervention can be initiated earlier, reducing
CVD risk even further. Altogether, this is likely to explain
the large differences in predicted and observed absolute
risks that have led to poor calibration.
To further investigate the difference between the study
populations, the model was fitted on our data and the
regression coefficients were compared with the original
values of the UKPDS risk engine. The greatest difference
was observed for sex, with women having a slightly greater
risk compared with men in our population, which is
Fig. 1 Calibration plots for 5 year calculated risk for (a) CHD and (b)
CVD. Values depict observed and predicted values with 95% CI. The
dotted 45° line denotes ideal agreement between predicted and
observed risk. Results based on first analysis (censored cases
excluded)
Table 3 Discrimination and calibration of the UKPDS risk engine for calculated risk periods of 4, 5, 6 and 8 years, with CVD as outcome
Calculated risk
period (years)
First analysis Second analysis
Cases/nc -statistic (95% CI) χ
2 statistic Cases/nc -statistic (95% CI) χ
2 statistic
4 67/1,510 0.66 (0.52–0.80) 25.2 (p=0.023) 67/1,622 0.65 (0.52–0.79) 32.1 (p=0.002)
5 78/1,479 0.66 (0.53–0.79) 35.2 (p=0.002) 78/1,622 0.65 (0.53–0.79) 48.1 (p<0.001)
6 94/1,442 0.66 (0.55–0.77) 41.6 (p<0.001) 94/1,622 0.65 (0.54–0.77) 62.2 (p<0.001)
8 122/1,100 0.65 (0.55–0.76) 29.7 (p=0.008) 122/1,622 0.64 (0.54–0.74) 106.0 (p<0.001)
First analysis: excluding participants with follow-up shorter than calculated risk period
Second analysis: including participants with follow-up shorter than calculated risk period
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might be explained by different lifestyles between men and
women in 1977 and nowadays. More men tended to smoke
in 1977 which, combined with starting smoking at an
earlier age, may have increased the CVD risk in men at this
time [23].
The current cohort was established between 1993 and
1997 and differences in lifestyle between men and women
may have changed over time, probably resulting in the
observed change in the regression coefficient for sex.
Furthermore, to some extent it can be explained by the high
number of women in our population. When only the German
cohort, which has equal numbers of men and women, was
analysed, this difference in theCVD risk for women between
our cohort and the UKPDS was eliminated.
The results of this study are comparable with those of
other validation studies. Two studies observed a modest
discrimination (c-statistics 0.74, 0.67) and an underestima-
tion [5, 6] of CHD risk instead of an overestimation as we
and others observed [4, 7, 11]. Yet, the number of diabetes
patients in these studies was small (n=125, n=428).
Furthermore, one of these studies estimated 10 year CVD
and CHD risk, while the follow-up of their cohort was only
4 years [5]. A validation study in the EPIC-Norfolk
population observed a good discrimination and an overes-
timation of the 10 year CVD risk [4]. However, a slightly
different version of the UKPDS risk engine was validated,
which was designed to calculate CVD risk instead of CHD
risk [4]. Therefore, their results might not be directly
comparable with the results of our study. Combining our
results with the previous studies mentioned, we can
conclude that the performance of the UKPDS risk engine
for predicting CVD and CHD risks is only moderate to
poor. Nonetheless, Dutch, Canadian and UK guidelines
recommend using the UKPDS risk engine to calculate CHD
risk in general practice [13–15]. The UKPDS risk engine is
also used in large trials to calculate initial CHD risk [24]. It
may not be advisable to use the UKPDS risk engine to
calculate absolute risk as a basis to initiate treatment or to
use risk ranking based on the outcome of the UKPDS risk
engine, as performance of the UKPDS is moderate to poor.
Constructing a new diabetes-specific CVD risk model
might enhance accurate risk prediction, particularly if using
a more contemporary population. As treatment of diabetes
has improved over time, CVD risk has been lowered.
Furthermore, modifiable risk factors have changed over
time: smoking is less common and there are better
treatments for hypertension and to lower HbA1c concen-
trations. These developments have impacted on the associ-
ated risk for a cardiovascular event.
In summary, we observed that the UKPDS risk engine
severely overestimated CHD and CVD risks in patients
with type 2 diabetes. The discriminative ability was only
moderate to poor. The results from various subgroup
analyses were not substantially different. To enhance
prediction of CVD and CHD in patients with type 2
diabetes, there is a need to update or construct a new and
improved diabetes-specific model with better performance
and, more importantly, better external validity [25, 26].
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